{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:26:14Z","timestamp":1761895574717},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T00:00:00Z","timestamp":1349740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Follicular lymphoma (FL) is the most common type of indolent non\u2010Hodgkin lymphoma. Although the introduction of the anti\u2010CD20 monoclonal antibody rituximab has represented a major breakthrough, FL remains incurable with standard chemoimmunotherapies. The goals of therapy in <jats:italic>symptomatic<\/jats:italic> FL patients include the following: obtaining high response rates, extending the duration of remission, prolongation of survival and improving quality of life, while minimizing adverse events. To extend remission duration and possibly survival outcomes, maintenance therapy with rituximab has been shown to be effective in both frontline and relapsed\/refractory settings. However, the optimal timing, schedule and length of maintenance therapy are controversial. Herein, we review the current data for maintenance rituximab in FL, discuss the current controversies for this modality, attempt to define its role relative to the more conservative <jats:italic>retreatment<\/jats:italic> approach and provide practical recommendations for its clinical use. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2033","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T08:52:21Z","timestamp":1349772741000},"page":"171-178","source":"Crossref","is-referenced-by-count":4,"title":["Rituximab maintenance versus retreatment in follicular lymphoma"],"prefix":"10.1002","volume":"31","author":[{"given":"Amruth R.","family":"Palla","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Danbury Hospital  Danbury CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Myeloma and Lymphoma Program, Section of Hematology and Oncology West Virginia University  Morgantown WV USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481101800405"},{"issue":"5","key":"e_1_2_11_3_1","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-011-0099-5"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi320"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.059246"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185280"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"issue":"21","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V116.21.6.6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non\u2010bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis","volume":"16","author":"Ardeshna K","year":"2010","journal-title":"Blood"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0560-2"},{"issue":"15","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/jco.2010.28.15_suppl.8005","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high\u2010dose therapy as in vivo purging and to maintain remission following high\u2010dose therapy","volume":"28","author":"Pettengell R","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr418"},{"issue":"21","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.V118.21.777.777","article-title":"Brief chemoimmunotherapy R\u2010FND with rituximab consolidation followed by randomization between rituximab maintenance vs observation as first line treatment in elderly patients with advanced follicular lymphoma (FL): final results of a prospective randomized trial by Italian Lymphoma Foundation (FIL)","volume":"118","author":"Vitolo U","year":"2011","journal-title":"Blood"},{"issue":"21","key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"LBA\u20106","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6","article-title":"Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma","volume":"118","author":"Kahl B","year":"2011","journal-title":"Blood"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh425"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds202"},{"issue":"21","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V118.21.3066.3066","article-title":"Favorable impact of post\u2010ASCT consolidative immunotherapy with rituximab, rINF\u2010a2b and rIL2 on overall survival and progression\u2010free survival in advanced stage or relapsed\/refractory follicular lymphoma: results of a phase II study","volume":"118","author":"Eveillard J","year":"2011","journal-title":"Blood"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.382"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.171"},{"issue":"11","key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood.V110.11.3420.3420","article-title":"Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group protocol E4402: rituximab extended schedule or re\u2010treatment trial (RESORT)","volume":"110","author":"Kahl B","year":"2007","journal-title":"Blood"},{"issue":"21","key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.V116.21.1802.1802","article-title":"Rituximab maintenance treatment for a maximum of 5\u2009years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35\/03","volume":"116","author":"Taverna C","year":"2010","journal-title":"Blood"},{"issue":"9","key":"e_1_2_11_36_1","first-page":"590","article-title":"Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma","volume":"36","author":"Fowler NH","year":"2011","journal-title":"P T"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802120028"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11314070-000000000-00000"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.694429"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.020"},{"issue":"21","key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood.V116.21.3945.3945","article-title":"Maintenance rituximab every 2\u2009months for 2\u2009years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: updated results from the phase IIIb MAXIMA study","volume":"116","author":"Foa R","year":"2010","journal-title":"Blood"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0113-5"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2033","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:03:26Z","timestamp":1700629406000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,9]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/hon.2033"],"URL":"https:\/\/doi.org\/10.1002\/hon.2033","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,9]]}}}